Cathepsin C Inhibitors: Property Optimization and Identification of a Clinical Candidate.
Furber, M., Gardiner, P., Tiden, A.K., Mete, A., Ford, R., Millichip, I., Stein, L., Mather, A., Kinchin, E., Luckhurst, C., Barber, S., Cage, P., Sanganee, H., Austin, R., Chohan, K., Beri, R., Thong, B., Wallace, A., Oreffo, V., Hutchinson, R., Harper, S., Debreczeni, J., Breed, J., Wissler, L., Edman, K.(2014) J Med Chem 57: 2357
- PubMed: 24592859 Search on PubMed
- DOI: https://doi.org/10.1021/jm401705g
- Primary Citation Related Structures: 
4CDC, 4CDD, 4CDE, 4CDF - PubMed Abstract: 
A lead generation and optimization program delivered the highly selective and potent CatC inhibitor 10 as an in vivo tool compound and potential development candidate. Structural studies were undertaken to generate SAR understanding.
- AstraZeneca , Pepparedsleden 1, Mölndal 431 83, Sweden.
Organizational Affiliation: 


















